Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Issue 19, pp 37–41 | Cite as

Kardio-metabolische Risikoreduktion

Welche Zielwerte sind bei Typ-2-Diabetes relevant?

  • Stephan JacobEmail author
FORTBILDUNG . SCHWERPUNKT
  • 43 Downloads

Typ-2-Diabetiker sind kardiovaskulär besonders gefährdet. Eine reine HbA1c-Fokussierung zur Risikoreduktion ist aber nicht mehr zeitgemäß. Die Therapie muss auch eine konsequente Blutdruck- und LDL-Cholesterin-Kontrolle erreichen.

Prevention of CV complications in DM2 — which targets should be used?

Keywords

Cardiometabolic risk management type 2 diabetes treatment targets 

Literatur

  1. 1.
    ADA: American Diabetes Association Standards of Medical Care in Diabetes—2019; Diabetes Care 2019 Jan; 42(Supplement 1): S103-S123.Google Scholar
  2. 2.
    Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 Oct;36(10):1953–2041.CrossRefGoogle Scholar
  3. 3.
    Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), European Heart Journal,, ehz455,  https://doi.org/10.1093/eurheartj/ehz455
  4. 4.
    Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018 Dec;61(12):2461–2498CrossRefGoogle Scholar
  5. 5.
    Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferoviæ PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019 Aug 31pii: ehz486. doi: 10.1093Google Scholar
  6. 6.
    McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bĕlohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Sep 19. doi:  https://doi.org/10.1056/NEJMoa1911303. [Epub ahead of print]
  7. 7.
    Eeg-Olofsson K, Zethelius B, Gudbjörnsdottir S, Eliasson B, Svensson AM, Cederholm J: Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. Diab Vasc Dis Res. 2016 Jul;13(4):268–77CrossRefGoogle Scholar
  8. 8.
    Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018 Aug 16;379(7):633–644.CrossRefGoogle Scholar
  9. 9.
    Eckel, RH, Blaha, MJ: cardiometabolic Medicine: A Call for a New Subspeciality Training Track in Internal Medicine, AM J Med, 2019: 7; 132, 788-790Google Scholar
  10. 10.
    Krentz AJ, Jacob S: Cardiometabolic medicine: time to recognize a new clinical specialty? Cardiovascular Endocrinology & Metabolism 2019, 8:47–48Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Villingen-SchwenningenDeutschland

Personalised recommendations